Aristopharma Ltd



Aristopharma has launched Canalia Capsule (A Proton Pump Inhibitor)

Canalia Capsule is the only US FDA approved Proton Pump Inhibitor formulated with Dual Delayed Release (DDR) technology that ensures faster action and longest acting Proton Pump Inhibitor. Canalia Capsule ensures higher 24-hour heartburn free periods and with just one capsule provides similar effects as twice-daily conventional Proton Pump Inhibitors therapy. Canalia Capsule is safe for cardiac patients as Dexlansoprazole has no clinically important effect on the active metabolite of Clopidogrel. It is a novel Proton Pump Inhibitor which doesn’t prolong QT intervals in healthy participants and is well-tolerated, so it is considered safe for the heart.